Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors

30 Jul 2018

Abstract excerpt

Inactivating mutations of the succinate dehydrogenase subunit B ( SDHB ) gene and the subsequent stabilization and activation of the hypoxia-inducible factor 2-alpha (HIF2α) unit are recognized hallmarks associated with the development of metastatic pheochromocytomas and paragangliomas (MPPG). Despite this discovery, the development of systemic therapies for patients with MPPG has been very slow. The rarity of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal and Paraganglionic Tumors
Share to Cancer, Hypoxia, and Metabolism
Share to Hormonal Regulation and Hypertension

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30109021
DOI: 10.12688/f1000research.13995.1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitorsPMID 30109021Read ↗

Current and Future Therapeutic Approaches for Metastatic Pheochromocytoma and Paraganglioma: Focus on SDHB TumorsSemantic proximity Read ↗

HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshopSemantic proximity Read ↗

Metastatic pheochromocytoma and paraganglioma.Semantic proximity Read ↗

Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.Semantic proximity Read ↗

New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomasSemantic proximity Read ↗

Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.Semantic proximity Read ↗

Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroupsSemantic proximity Read ↗

Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma-Case Report and Review of the Literature.Semantic proximity Read ↗

MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma.Semantic proximity Read ↗

Durable and deep response to CVD chemotherapy in SDHB-mutated metastatic paraganglioma: case report.Semantic proximity Read ↗

Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.Semantic proximity Read ↗

SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.